

# 간세포성장인자가 하인두 편평세포암 세포주에서 Matrix Metalloproteinase (MMP) -2, 9과 Urokinase Type Plasminogen Activator에 미치는 영향

김철호<sup>1</sup> · 문성균<sup>1</sup> · 배준호<sup>1</sup> · 이재호<sup>2</sup> · 최은창<sup>3</sup>

## Effect of HGF in Invasion of Hypopharyngeal Squamous Cell Carcinoma Cell Line

Chul-Ho Kim, MD<sup>1</sup>, Sung-Kyun Moon, MD<sup>1</sup>, JunHo Bae, MD<sup>1</sup>, JaeHo Lee, MD<sup>2</sup> and Eun Chang Choi, MD<sup>3</sup>

<sup>1</sup>Department of Otolaryngology and <sup>2</sup>Biochemistry, Ajou University School of Medicine, Seoul; and

<sup>3</sup>Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea

### ABSTRACT

**Background and Objectives** : Recent reports revealed that hepatocyte growth factor (HGF) is related to tumor invasion and metastasis. Activation of the urokinase-type plasminogen activator (u-PA)/plasmin proteolytic network and matrix metalloproteinase has been shown to play a key role in tumor invasion and dissemination of various malignancies. So we examined the effect of HGF/c-Met on MMP-2, 9 and u-PA in FaDu cell, a hypopharyngeal squamous cell carcinoma cell line. **Materials and Method** : We performed RT-PCR and Western blot in FaDu. Tumor cell invasiveness was assessed by the membrane invasion assay (using Transwell chamber). To examine the role of MMP-2, 9 and the relation between HGF and MMP in the invasion of hypopharyngeal cancer, RT-PCR and zymography were performed in FaDu cells. We tested to confirm the HGF-mediated plasmin activation. **Results** : The expressions of c-Met mRNA and protein were detected in the hypopharyngeal cell line while that of HGF was not. HGF markedly enhanced the invasion of cancer cells in a Transwell invasion chamber in a dose-dependent manner ( $p < 0.05$ ). The expression of MMP was detected in hypopharyngeal cancer cells and exogenous HGF slightly enhanced the induction of MMP-2 activity in zymogram analysis. The activity of u-PA was detected in FaDu and HGF (above 10 units/mL) enhanced the activity of u-PA ( $p < 0.05$ ). **Conclusion** : These results suggest that HGF may play an important role in hypopharyngeal cancer through the activation of u-PA and matrix metalloproteinase. (Korean J Otolaryngol 2005;48:788-95)

**KEY WORDS** : Hepatocyte growth factor · c-Met, Hypopharyngeal cancer · Invasion · Urokinase-type plasminogen activator · Matrix metalloproteinase.

가 가 가 가 가<sup>1)</sup>

: 2004 11 2 / : 2005 1 4 matrix metalloproteinase(MMP) serine protease가 . MMP

: (031) 219 - 5267 · : (031) 219 - 5264  
E - mail : smoon@ajou.ac.kr

<sup>2)</sup> serine protease  
 urokinase - type plasminogen activator(u - PA)가  
<sup>3)4)</sup>  
<sup>5)</sup>  
 (hepatocyte growth factor, HGF)  
 ,  
 protease  
 (motility) (invasiveness)  
 (morphogenesis) (angio-  
 genesis)  
<sup>6)7)</sup>  
 MMP u - PA HGF  
 c - Met  
 가  
<sup>8)9)</sup>  
 가  
 HGF/c -  
 Met가 MMP  
 u - PA .  
 American Type Culture Collection(ATCC)  
 FaDu(HTB - 43, ATCC) EMEM  
 (10% FBS) 5% CO<sub>2</sub>, 37 . u -  
 PA assay Madin - Darby canine  
 kidney(MDCK - 2) 10% FBS가 DMEM  
 .  
 HGF human HGF affinity puri-  
 fied polyclonal goat antibody(R & D systems, Inc, MN,  
 USA) c - Met human  
 HGF receptor(c - Met) polyclonal goat antibody(R &  
 D system) .  
 RT - PCR HGF c - Met mRNA  
 1 mL TRIzol<sup>®</sup>(GIBCOBRL, Grand Is-  
 land, NY, USA) , RNA  
 . RNA 2 μg  
 Omniscript Reverse Transcriptase kit(20511, Qiagen  
 Germany) {10X Buffer RT 2.0 μL, dNTP  
 Mix(5 mM each dNTP) 2.0 μL, Oligo - dT primer(10  
 μM) 2.0 μL, RNase inhibitor(10 units/μL) 1.0 μL, Om-  
 niscript Reverse Transcriptase 2 units, RNase - free  
 water} 20 μL 37 60 , 94 5  
 cDNA . PCR Minicycler<sup>™</sup>(MJ  
 research, USA) cDNA Taq DNA  
 polymerase 1 unit(Roche Diagnostics Co, Indianapolis,  
 USA) primer .  
 human HGF primer human c - Met primer  
 .  
 human HGF ;  
 sense : 5 ' - ACA TCG TCA CTT CTG GC - 3 '  
 antisense : 5 ' - ATC CAT CCT ATG TTT GTT  
 CG - 3 '  
 human c - Met ;  
 sense : 5 ' - AGT AGC CTG ATT GTG CAT TT - 3 ;  
 antisense : 5 ' - TCT TTC ATG ATG CCC TC - 3 ;  
 - Actin ;  
 sense : 5 ' - TCA TGA AGT GTG ACG TTG ACA  
 TCC TT - 3 ;  
 antisense : 5 ' - CCT AGA AGC ATT TGC GGT GCA  
 CGA TG - 3 ;  
 PCR 96 3 , 96  
 30 , 55 30 , 72 30 30  
 cycles (extension) 72 5  
 .  
 Western blotting c - Met  
 phosphate buffered saline(PBS)  
 (100 μg/mL phenylme-  
 thylsulfonyl fluoride, 1 μg/mL leupeptin)가 가 RIPA  
 (RadioImmunoPrecipitation) buffer 1 mL{150 mM NaCl,  
 1% NP - 40, 50 mM Tris(pH 8.0), 1 mM EDTA, 0.5% De-  
 oxycholate} . 15,000  
 rpm 10 Western blot an-  
 alysis Bio - Rad protein  
 assay(Bio - Rad, Hercules, CA USA)  
 . Well 20 μg sodium do-  
 desyl sulfate(SDS) - polyacrylamide gel electrophoresis  
 (PAGE) nitrocellulose filter(Amer-

HGF가 하인두 편평세포암종의 침습에 미치는 영향

sham, Arlington Heights, IL. USA) 4  
 c - Met filter  
 0.1% Tween - 20 Tris buffered saline(TBS)  
 peroxidase - conjugated donkey anti - rabbit antibody(Amersham) donkey anti - mouse antibody(Amersham) enhanced chemiluminescence detection system(ECL, Amersham)  
 X - ray film

HGF  
 HGF 가  
 Transwell chamber(Costar) polyethylene filter(8 µm pore - sized)  
 EMEM 100 µL type I collagen(6 µg/filter) laminar flow hood coating  
 well 0.5% FBS medium 500 µL HGF 0, 10, 30 ng/µL well  
 Mitomycin C(8 µg/mL) 30 well  
 filter 10<sup>5</sup> cells(in 100 µL of growth medium) (Fig. 2). chamber 37 , 5% CO<sub>2</sub> 48  
 well filter pore  
 hematoxylin

matrix metalloproteinase(MMP) - 2, 9  
 zymogram

RT-PCR를 이용한 MMP의 발현도 검사  
 FaDu 50~100 mg  
 mRNA  
 MMP - 2 primer MMP - 9 primer

MMP - 2 ;  
 sense : 5 ' - ACC TGG ATG CCG TCG TGG AC - 3 '  
 antisense : 5 ' - TGT GGC AGC ACC AGG GCA GC - 3 '  
 MMP - 9 ;  
 sense : 5 ' - GGG GAA GAT GCT GCT GTT CA - 3 '  
 antisense : 5 ' - GGT CCC AGT GGG GAT TTA CA - 3 '  
 PCR 96 3 96  
 30 , 55 30 , 72 30 30

cycles (extension) 72 5

Zymogram analysis  
 HGF 0, 10, 30 ng/mL  
 1, 2  
 30 µg APMA 15  
 µL 가 37 1  
 MightySlim™ SX 250(Hoefer, CA, USA)24 48  
 10 µL sample  
 buffer 10 gel  
 Novex XCell II 4 125V 120  
 60 renaturing buffer  
 developing buffer 100 mL 37  
 fresh developing buffer 가 18  
 3 Coomassie blue  
 10  
 (Methanol 400 mL, Acetic acid 100 mL, Distilled water 500 mL) Gel image analyzer

HGF가 Urokinase type Plasminogen activator  
 10% FBS가 DMEM 96 well  
 plates (3000 cells/well, 6000 cells/well)  
 (MDCK - 2 1500 cells/well  
 plate set plasmin  
 well HGF 0,  
 1.25, 2.5, 5, 10, 20 units/ml 24

Plasmin 활성도 측정  
 phenol red가 DMEM reaction buffer  
 200 µL {50%(v/v) 0.05 U/mL plasminogen in DMEM (without phenol red), 40%(v/v) 50 mM Tris buffer (pH8.2), 10%(v/v) 2.25 mM chromozyme PL in 100 mM glycine solution} 37 , 5% CO<sub>2</sub>  
 3 405 nm automated spectrophotometric plate reader

세포의 증식 측정  
 4 , 50% trichloroacetic acid 20

deionized water 5 . sulforo-  
damine B(SRB)(100 μL/well, 0.4%(w/v) in 1% acetic  
acid) well plate 30  
Unbounded SRB 1% acetic  
acid 570 nm automated sp-  
ectrophotometric plate reader

HGF 24 , 48  
PCR HGF 10 ng/mL  
가  
가  
MMP - 9  
가 (Fig. 4).  
MMP - 2  
RT -  
HGF  
HGF 30 ng/mL  
HGF

one - way ANOVA test  
Scheffe test . p 0.05

Zymogram analysis  
MMP - 2, 9 HGF  
zymogram  
MMP 가  
가 MMP  
가 MMP - 2  
가  
24 zymogram HGF 10 ng/mL  
가 가 48  
zymogram HGF 30 ng/mL  
가 가 . MMP - 9  
48 zymogram HGF 30 ng/mL  
가  
가 가

RT - PCR Western blotting  
RT - PCR HGF  
c - Met Western  
blotting c - Met (Fig. 1).

(Fig. 5).

HGF  
Transwell chamber type I collagen coating  
19 HGF  
10 ng/mL 89 HGF 30 ng/mL  
136 HGF  
chamber 가 Transwell  
0.05), HGF 30 ng/mL 가 10 ng/mL (p<  
가 (Fig. 3).




Fig. 2. Transwell chamber used in invasion assay.

matrix metalloproteinase(MMP) - 2, 9  
zymogram

RT-PCR를 이용한 MMP의 발현도 검사  
HGF가 MMP - 2 MMP - 9






Fig. 1. Expression analysis of c-Met and HGF in FaDu cell line. A : The expression of c-Met mRNA on RT-PCR were detected in hypopharyngeal cancer line (FaDu cells) B : The protein of c-Met on Western blotting were detected in FaDu cells. However, HGF was not detected in the RT-PCR and Western blotting.


HGF가 하인두 편평세포암종의 침습에 미치는 영향



**Fig. 3.** Invasion assay. FaDu cells seeded on the upper membrane in the presence (10, 30 ng/mL) or absence of recombinant HGF in the lower compartment. After 48 hour of incubation, plugged cells in 8  $\mu$ m pore or cells attached to the under-surface or the membrane were counted. The bars show SD of triplicate samples. Data are representative of 3 separate experiments with similar results. \* $p < 0.05$  when compared with that of control by ANOVA test. HGF enhanced the invasion of FaDu cells in a Transwell invasion chamber in a dose-dependent manner ( $p < 0.05$ ).



**Fig. 4.** RT-PCR of MMP-2, 9 in FaDu cells. The expression of MMP was detected in FaDu cells and exogenous HGF (30 ng/mL) slightly enhanced expression of MMP-2.



**Fig. 5.** Induction of MMP-2, 9 activity by HGF. FaDu cells were serum-deprived for 48 hours, then incubated with fresh medium containing HGF (10, 30 ng/mL). Conditioned medium were collected at 24 hours and 48 hours respectively. Samples were fractionated on a polyacrylamide gel containing 0.1% gelatin and zymogram was developed as described in Material and Methods. Migration of the 92-kDa and 72-kDa gelatinase activities as determined from molecular weight standards are indicated by the solid arrows.

HGF가 Urokinase type Plasmin activator

MDCK2

HGF

plasmin 가 가

(>0.05).

3  $\times 10^3$  가 가 HGF

plasmin 가 가 (Fig. 6).

well 6  $\times 10^3$

HGF 가

(Fig. 6A), SRB HGF 5

unit/ml 가 10 unit/mL 5 unit/mL

plasmin 가 가



HGF가 하인두 편평세포암종의 침습에 미치는 영향

system angiogenesis growth factor bFGF VEGF 48 24  
 tatin angiostatin natural angiogenesis inhibitor endos- incubation MMP - 2 modest down -  
 regulation MMP HGF .<sup>11)</sup>  
 Trusolino (human mammary adeno- carcinoma cell line)가 MMP - 9 uPA  
 HGF MMP가<sup>12)</sup>  
 MMP HGF가 MMP 가  
 RT -  
 PCR MMP 가  
 MMP - 2 MMP - 9  
 HGF MMP 가 MMP - 2 HGF MMP  
 30 ng/mL 가 tissue - type plasminogen activator(t - PA) uro-  
 HGF mRNA 가 kinase - type plasmingen activator(u - PA)가 ,  
 , zymography t - PA , u - PA<sup>19)20)</sup> u - PA  
 MMP - 2, 9 가  
 MMP - 2가 52kD serine protease  
 MMP가 가  
 HGF MMP - 2 u - PA proenzyme pro -  
 HGF 가 가 uPA plasmin  
 MMP - 9 HGF 30 ng/mL .<sup>21)</sup> u - PA plasminogen pla-  
 48 smin 가 , 가 plasmin  
 가 RT - PCR MMP - 2 HGF fibrin, fibronetin, proteo-  
 glycan, laminin , type collagenase  
 type collagen<sup>21)</sup>  
 m - RNA 가가 .  
 protein 가 u - PA  
 가 , ELISA(enzyme - linked  
 immunoabsorbent assay) u - PA  
 RT - PCR Western blot MMP protein (immunoreactivity)<sup>22)</sup> <sup>23)</sup>  
 가 Horie  
 HGF/c - met signal (renal  
 cell carcinoma cell line, Caki - 1) proMMP9, pro-  
 MMP1, urokinase - type plasminogen activator(uPA)  
 upregulation<sup>8)</sup> Kawamata HGF FaDu  
 proMMP9 MMP - 2가 Transwell chamber MMP  
 HGF MMP<sup>9)</sup> HGF가 u - PA  
 가<sup>23)</sup>  
 EGF, TGF, HGF가 8 MMP - 2가 FaDu  
 MMP - 9 MMP - 2 MMP u - PA가

HGF 가 .  
 가 HGF가 (FaDu) MMP - 2 u -  
 PA가 HGF가 MMP - 2 u - PA  
 가 .  
 가 HGF MMP u -  
 PA 가가 .  
 : . c - Met . .  
 urokinase - type plasminogen activator · matrix metallo-  
 proteinase.

REFERENCES

- 1) Liotta LA, Steeg PS, Stetler-Stevenson WG. *Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell* 1991;64:327-36.
- 2) Tryggvason K, Hoyhtya M, Pyke C. *Type IV collagenases in invasive tumors. Breast Cancer Res Treat* 1993;24:209-18.
- 3) Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. *Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res* 1981;41:4629-36.
- 4) Schmitt M, Janicke F, Graeff H. *Tumour-associated fibrinolysis: The prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis* 1990;1:695-702.
- 5) Slingerland J, Pagano M. *Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol* 2000;183:10-7.
- 6) Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. *Scatter factor: Molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol* 1990;111:2097-108.
- 7) Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. *Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A* 1993;90:1937-41.
- 8) Horie S, Aruga S, Kawamata H, Okui N, Kakizoe T, Kitamura T. *Biological role of HGF/MET pathway in renal cell carcinoma. J Urol* 1999;161:990-7.
- 9) Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro KI, Hino S, et al. *Active-MMP2 in cancer cell nests of oral cancer*

- patients: Correlation with lymph node metastasis. Int J Oncol* 1998; 13:699-704.
- 10) Kim CH, Moon SK, Bae JH, Lee JH, Choi EC. *Effect of HGF in proliferation, dispersion and migration of hypopharyngeal squamous cell carcinoma. Korean J Otolaryngol. In press.*
- 11) McCawley LJ, O'Brien P, Hudson LG. *Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)-mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol* 1998;176:255-65.
- 12) Trusolino L, Cavassa S, Angelini P, Ando M, Bertotti A, Comoglio PM, et al. *HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. Faseb J* 2000;14:1629-40.
- 13) Ridley AJ, Comoglio PM, Hall A. *Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol* 1995;15:1110-22.
- 14) Vadnais J, Nault G, Daher Z, Amraei M, Dodier Y, Nabi IR, et al. *Autocrine activation of the hepatocyte growth factor receptor/met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion. J Biol Chem* 2002;277:48342-50.
- 15) Jin SM, Lee SH, Choi G, Choi JO. *Expression of Matrix-Metalloproteinase-2, Urokinase-Type plasminogen activator and plasminogen activator inhibitor mode and lymph node metastasis of laryngeal squamous cell carcinoma. Korean J Otolaryngol* 1998;41:1169-73.
- 16) Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, et al. *Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg* 1994;81:69-77.
- 17) Overall CM, Lopez-Otin C. *Strategies for MMP Inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer* 2002;2:657-72.
- 18) Rha SY. *Zymography. Biotechnology Transfer in Cancer Metastasis Research*;2003. p.73-84.
- 19) Folkman J. *Tumor angiogenesis: Therapeutic implications. N Engl J Med* 1971;285:1182-6.
- 20) Dray TG, Hardin NJ, Sofferan RA. *Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol* 1995;104:724-9.
- 21) Folkman J. *What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst* 1990;82:4-6.
- 22) Grigioni WF, D'Errico A, Fortunato C, Fiorentino M, Mancini AM, Stetler-Stevenson WG, et al. *Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol* 1994;7:220-5.
- 23) Kim CN, Chung SM, Min JH, Kim SS, Kim MY. *An immunohistochemical study on the expression of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-2 and angiogenesis in human laryngeal squamous cell carcinoma. Korean J Otolaryngol* 1997; 40:671-81.